Speaking from the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, Francesca Gay, MD, of the University of Turin, Turin, Italy, discusses the practical implications of immunomodulators as a form of multiple myeloma (MM) treatment, the effects of these drugs both in the short and long term, and how to manage their most common side effects. Dr Gay also refers to lenalidomide, currently administered to autologous transplant patients, before discussing the difficulties in determining whether treatment should be adjusted based on positive or negative measurable residual disease (MRD) status.
